Purpose: Immunohistochemistry (lHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose of this study was to evaluate the ability of ER status determination by IHC, compared with LBA, to predict clinical outcomeespecially response to adjuvant endocrine therapy-in a large number of patients with long-term clinical follOW-Up.
used to define ER positivity on the basis of a univariate cut-point analysis of all possible scores and disease-free survival (DFS) in patients receiving any adjuvant endocrine thera py.' Using this definition, 71 % of a II' tumors were determined to be ER-posltive by IHC, and the level of agreement with the LBA was 86%. In multivariate analyses of ,patients receiving adjuvant' endocrine therapy alone, ER status determined by IHC was better than that determined by'the LBA at predicting improved DFS.(hazard ratios/P =0.474/.0008 and 0.707/.3214, respectively) and equivalent at predicting overall survival (0.379/.0001 and 0.381/.0003, respectively).
Conclusion: IHC is superior to the LBA for assessing ER status in primary. breast cancer because it is easier, safer, .and less expensive, and has an eqUivalent or better ability to predict response to adjuvant endocrine therapy. large amounts offresh-frozen tissue; and are insensitive and nonspecific' in accounting for differences in the cellular composition of samples, such as those with a low tumor ,cellularity or contaminating benign cells that might be ER-positive.
The development of highly specific monoclonal antibodies s and immunohistochemistry (IHC) techniques to localize ERs6 provided the potential' to overcome most of the difficulties inherent to LBAs. Compared with LBAs, IRC is easier to perform, less expensive, safer, applicable to a wider variety of samples (eg, cytologic preparations. frozen tissue sections, fixed archival tissue sections, etc), and more sensitive and specific in the identification of rare ERpositive tumor cells or contaminating ER-positive benign epithelium under direct microscopic visualization.
The ultimate usen.lli,ess of ER status asseSslnent by THe. however, resides in its ability to predict clinical outcome, especially response tohomlone therapy. Many 'studies have evaluated the clinicaLrelevance of measuring ERstatus by IRC,and the largemajority'reportedstatisticallysignificant relationships with clinical outcome. 7 Nonetheless, there were limitations associated with these generally positive " studies. For example, the majority evaluated patient populations of mixed clinical stage and treatment statUs, making it nearly impossible to separate the prognostic . . . from the predictive implications of their results. In addition, these studies used many different antibodies and detection syst erns with unequal sensitivities and specificities on tissue samples prepared in diverse ways. The most problematic aspect was the use of a wide variety of techniques for scoring and interpreting results with arbitrary rather than clinically calibrated definitions of ER positivity. Despite these largely unresolved issues, most laboratories today have already. converted to assessing ER status almost exclusively by IHC on routine archival (ie, fOffilalin-fixed paraffin-embedded) tissue samples.
The purpose of this· study was to resolve some of these issues by developing an IHC assay' for archival tissue, using .inexpensive commercially available reagents. and an easy, reproducible scoring system calibrated to clinical out~ome. The prognostic and predictive usefulness of this IHC assay was evaluated and compared with a standard LBA in a large group of patients with primary br:east cancer and long-tem1 clinical follow-up.
PATIENTS AND METHODS

Patient Population
Tumor specimens fTom patients with primary breast cancer in the San Anto~io Tumor Bank were included in this study. Patients were diagnosed between 1973 and 1993 and had their ER statuses evaluated by LBAat the time of diagnosis in our laboratory. Selection criteria included presentation with primary brea~t cancer, sufllcient tumor tissue remaining after LBA for additional lHC assays, and long-tenn follow-up for disease recurrence and death. A total of 1,982 patients who satisfied these criteria were chosen: 997 with negative axillary lymph nodes and 985' with positive nodes. Surgical" treatment included modified radical mastectomy in 91 % of the patients and lumpectomy in 9%. Postoperative radiation was used in 21 %.. After surgelY. 35% received no additional therapy. The rem:'linder received systemic adjuvant therapy in a routine clinical setting; this therapy consisted of 'chemotherapy alone in 13%, endocrine therapy alone in 26%, and combined chemotherapy and endocrine therapy in 13%. The status of adjuvant therapy was unknown in 5%. Patients were observed for disease recurrence and death as previously described.~A total of 620 patients (31 %) had experienced disease recurrence, and 734 (37%) had died by the time of analysis. The median follow~up period for patients still alive at the time of analysis was 65 months (range, 1 to 214 months).
LBAjorER
Breast tumor specimens were frozen in liquid nitrogen immediately after excision and then sent to the Steroid Receptor Laboratory at the University of Texas Health Science Center at San Antonio. The tumor tissues were pulverized in .liquidnitrogen. andcytosolswcrcprepared foriheLBA·aspreviousIYdescri6ed.~I~r{lnl······f97~fiol984.·· J Ffesilidi·ol was used as the labeled ligand: Since 1985. the standard multipoint DCCA had been modified to incorporate 1251-labeled estradiol and 3H~R5020 in a single assay, allowing for the simultaneous determination of both ER and progesterone receptor statuses. Tumors with an ER content of~3 fmol/mg protein (the limit of detection in this assay) were considered to be ER-positive, based on" studies calibrated to ' clinical outco~e.IO'12 The pulverized tissue that remained after the corticosteroid receptor assay was performed was stored at -70°C for future use.
IHCforER
Tissue sections for ER status determination by lHC were prepared from the pulverized frozen tumor specimens left over from the LBA as previously described.J3 Because of the ultiacold temperature used' during pulverization, the tissue was fractured into histologically intact fragments ranging from approximatelyO.1 to 1.0 min in size. Individual samples consisted of 100-mg pellets of this particulate tissue, which was fixed for 6 to 8 hours in 10% neutral buffered formalin and routinely processed to pardffin blocks. Histoiogic sections from these samples resemble thelarge~core needle biopsies in routine clinical use today.13 The I HC assay was performed .on 4 /lm sections cut from the blocks and float~mounted on adhesive (silanized) glass slides. The essential techniques ofthe IHCassay included retrieving the antigen in 0.1 M boiling citrate buffer (pH 6.0) ina pressure cooker; blocking endogenous peroxidase with 0.1% sodium azide and 0.3% hydrogen peroxide; blocking nonspecific protein binding with 10% ovalbumin; binding with primary mouse monoclonal antibody 6Fll against the ER (Vector Laboratories, Burlingame, CA) at a dilution of 1:40 for 2 hours; linking with biotinylated rabbit antibody against mouse immunoglobulin G(Dako Corp, Carpenteria, CA) at a dilution of 1:100 for 30 minutes; enzyme labeling withstreptavidin-horseradishperoxidase (Dako)at a dilution of I:] 00 for 30 minutes; developing chromogen with 0.03% hydrogen peroxide and I mg/mL diaminobenzidine;enhancing the signal with 0.2% osmium tetroxide; and counterstaining with methyl green. Human endocervix tissue wa's used as a positive control because 6f····iiseasya,;aiIabi Ii f);aridrehiiive lysiablereacii';·iiy.t'hc'llegati;,;e control consisted of nonimmune mouse immunoglobulin G substituted for the primary ER antibody. Controls were run with each batch of slides. at an average ofapproximately 50 slides per batch. The method produced a distinct nuclear signal in ER-positive tumor cells (Fig l) .
Immunostained slides were scored as previously described. 7 .14 [n brief, each entire slidewas~valuatedby light microscopy. First, a proportion score was assigned, which represented the,estimated proporD 1476 tion of positive-staining tumor cells (0, none; 1, < YiUI1; 2, \lIOn to \110; 3, Yin to \I.,; 4, 1,,1 to :!Jl; and 5, > :!h). Next, an intensity score was assigned, which represented the average intensity ofpositive tumor cells (0, none; I, weak, 2, intermediate; and 3, stTong). The proportion and intensity scores were then added to obtain a total score, which ranged from 0 to 8.
Slides were scored by pathologists who did. not have knowledge of ·ligand-binding results or patient outcome. Two pathologists (lM.H. and D.C.A.) were trained and calibrated to use of the IHC scoring system by simultaneously evaluating a panel of 200 breast cancer tissue samples that were immunostained for ER and which were not part of the study presented here. They then indepen· dentiy scored another 220 cases that were part of this study. Their results (total scores) on the second panel of tumors were in complete agreement in 71% of the. cases and within one [HC score in the remaining 29%. of the cases.· 'n,e weighted kappa statistic for concordance was 0.87 (P< .000 I). Taken together, these results indicated that the scoring method was easy to learn and highly reproducible. Because the concordance between the pathologists was so high during the training, all further scoring of cases in this study was carried out by one pathologist (J.M.H.).
Statistical Methods
Associations between continuous variables. were analyzed using nonparametric Spearman rank correlation coefficients. Associations between categorical variables were assessed by X 2 tests. Kappa statistlcs were used as measures of agreement between the different pathologists and between the two methods for determining ER status. An optimal cut point for defining ER positivity was determined bycomputing log-rank statistics for each of the seven possible cut points of the total IJ-/C score. Adjustments were made to the resulting P values. as suggested by Hilsenbeck and ClarkY Univariate disease~free survival (DFS) and overall survival (OS) curves were estimated by the metl10d of Kaplan and Meier and compared, using 10g·rank statistics. Cox proportional hazards regression models were created to assess the prognostic and predictive value of ER status in multivariate analyses. To adjust estimates of hazard ratios and their corresponding P values from Cox models for the mUltiple significance testing used to define the ER cut point, the following approach was used. The P value obtained from the . Cox model was multipl ied by seven (the number of possible cut points of the total IHC score). The Z statistic corresponding to this P value was obtained by inverting the cumu lative normal distribution function. An adjusted parameter estimate for ER status was computed as the product of the Z statistic and the reported SE of the parameter estimate, based on the assumption that the bias associated with· multipie significance testing primarily affects the magnitude of the parameter estimate rather than its SE. The adjusted hazard ratio and 95'% confidence limits were obtained by exponentiation of the adjusted parameter estimate and its· 95% confidence limits. Because all potential cut points are not biologically plausible and because this Bonferroni.type adjustment is known to be conservative: this techniqucprobably ovel"adjusts tor the multiple significance testing used to define the ·IHC ER cut point. All analyses were performed using SAS (Version 6.11; SAS Institute, Cary, NC}oh a Slln SparcServer 1·000··· system (Sun·····Microsystems;······lnc; Mountain View, CA).
RESULTS
Agreement Befl.veen IHC andLBAforER
A comparisonofthedistributionofIHC scores and _ ligand-binding values for ER status in the 1,982 tumors in this study is listed in 
Df4fining ER Positivity by IHC
To identify a clinically meaningful cut point for defining ER-positivc tumors, we examined DFS· curves for all possible IRe scores within the different treatment groups.
For patients receiving no. systemic adjuvant therapy (n = 701), ER status was only aweakprognostic factor, as expected. The log-rank P value. for the best cut point (IRC score> 4) in untreatedpatients was only maTJ:~inally significant (p.= .024) and became nonsignificant (P =.20) after adjustment for mUltiple significance testing.. For patients who received adjuvant chemotherapy alone (n = 407), no significant cut points were identified (all P > .40). However, for patients who received adjuvant endocrine therapy, either alone (n = 517) or in combination with chemotherapy (n = 260), ER status was a highly significant predictor of DFS. For these latter two groups combined (n = 777), the best cut point (THe score > 2) was highly significant (P < .0001) andremained soCP < .01) after adjustment for multiple significance testing. On the baSIS of these results, . tumors were defined as ER-positive if their total IHC score was greater than 2 and ER-negative if their score was Oor 2. Note ··that·· a total score·····of3, the······lowestpossible positive score, corresponds to as few as 1% to 10% weakly staining tumor cells. When this definition was applied to the 220 training cases that were independently scored by both study pathologists, only two cases (1 %) showed a discrepancy (ie, positive versus negative) in ER status, and in both cases, the tumors received a score of 2 by one pathologist and a score of 3 by the other (Fig 2) 
Clinical Utility a/Assessing ER by IHC f'ersus LSA
The associations between ER status and clinical outcome were independently evaluated for THe with unadjusted cut points; for IHe with adjusted cut points; for LBA using a cut point of 3 fmoVmg protein (LBA3, our clinically validated laboratory standard for 15 years); and for LBA using a cut point of 10 finollmg protein (LBA 10, a c~mmon international laboratory standard) ( Table 3 ). All, analyses were adjusted for the contributions of standard prognostic factors (including axillary lymph node status; tumor size, and patient age at diagnosis) by Cox modeling for proportional hazards regression.
In the subset of patients receiving no adjuvant therapy (n =688), ER positivity by LSA Ia showed a marginally significant association with improved DFS, whereas THC, adjusted THC, and LBA3 were not significantly associated with DFS. Positivity results determined by IHe, LBA3, and LBA1a all showed, significant associations with prolonged OS, whereas the association with adjusted IHC was marginal. Overall, the fractional hazard ratios for all statistically significant associations. observed in this nonrandomized. initially untreated group of patients were relatively large, emphasizing that ER status is a weak prognostic factor' regardless of how it is measured, and were probably due in large part to responses to endocrine therapy given after first .relapse in our study population.
In the subset of patients receiving adjuvant cytotoxic chemotherapy alone (n =404), ER status by IHC, adjusted lHC, and LBA3 were not significl:lntly related to DFS or OS. Time (months) 12 Best Cutpoint: IRe score >2 (p<0.0001)
Patients receiving any endocrine therapy (n = 777)
Using this definition ofER positivity, 70.5% of the 1,982 tumors in this srody were ER-positive by IHC (ie, total score > 2), compared with 78.9% by LBA. Overall concordance between the tests was 85.5%. The kappa statistic for concordance was 0.62 (P < .000 1). The remaining '14.5% of tumors had discordant results that fell into two groups. One group, comprising 11 A% of the tumors, was positive by LBA and negative by IRe. The LBA values were low (3 to 9 fmol/mg) in the majority of these tumors, but there was no overriding histologic explanation, such as the presence of ER-positive benign epithelium, to account for this discordant phenotype. The other group, comprising 3.1 % of the tumors, was negative by LSA and positive by IHC. Again, there was no pervasive histologic feature, such as rare ER-positive romor cells, that explained this discordant phenotype. When a cut point of 10 fmollmg was used to define ER positivity by ,LBA, a standard used in many reference laboratories worldwide, the concordance between LBAandIHC assays increased slightly, to 87.7%. Table 2 shows the associations between ERstatus by IHe and other standard prognostic factors. Patients with positive axillary lymph nodes or with hunors larger than 2 cm in diameterhad reducedfrcquenciesofERpositivity,(P=. 005 and P < .001, respectively). ER positivity increased with advancing age, from 46% in patients younger than 35 years of age at diagnosis, to 65% in patients 35 to 65 years of age, to 82% in patients older than' 65 (P < .00 1). Because this study was based on patients who had not been randomizedto treatment, the rates of ER positivity differed with treatment status, as expected. For example, only 43% of patients who 1.0 Fig 2. Univariate DFS curves for all possible total IHC scores in patients receiving any adjuvant endocrine therapy (almost always tamoxifen). An IHC score > 2 was the optimal cut point for predicting significantly improved outcome (P < .0001), and this value was used to define ER positivity throughout the study. LBA 10 showed a marginally significant association with OS but was unrelated to DFS., Overall, the results in this nonrandomized group of high-risk patients initially treated' with adjuvant chemotherapy also emphasize that ER status is a weakprognostic factor. In clinical practice, ER status' is used primarily as a predictive factor for response to adjuvant hormone therapy. rather than as a prognostic factor: In the subset ofpatients receiving adjuvant endocrine therapy alone (almost always tamoxifen; n = 517), ER positivity by IHC and 'adjusted IRC were both strongly associated with improved DFS (hazard ratioslP = 0.4231.0001 and 0.474/.0008, respectively) and OS (hazard,ratiosIP=0.352/.0001 and 0.379/. .0001, respectively). There were no significant associations between LBA3 or LBA 1oand DFS, although ER positivity HARVEY ET AL by both assays was associated' with' improved. OS .(hazard ratiosl? == 0.381/~0003 and 0.4331.0001, respectively). Overall, the results in this group of nonrandomized but similar patients emphasize that ER status is a strong 'factor for predicting response to adjuvant endocrine therapy and that IRC is somewhat better than LBAin this setting.
Associations ofER by lEe With Other Standard Prognostic Factors
In the subset 'of patients receiving combined' adjuvant chemotherapy and endocrine therapy (n = ,260), ER positivity results detenninedby IRC, adjusted IRC, LBA3, and LBA 10 all showed strong and essentially equivalent correlations with improved DFS and,OS, showing again that ER.is a strong predictive factor for response to endocrine therapy.
DISCUSSION
practice, theif primary use is as predictive markers to distinguish patients who have little Of no chance of benefiting from endocrine therapy from those who have some reasonable chance of benefiting. Thejustification for this endorsement was based on many studies conducted over the past two decades, involving patients in randomized clinical trials which showed that these tests were sufficiently sensitive, specific; and reproducible' to reliably identify subsets of patients' with' significantly different risks for recurrence, survival, or treatment response. 2 • 7 • 16 Nonetheless, many problems associated with LBAs have become increasingly urgent over the' years, including high cost, tecImical difficulty. reliance on radioactive reagents, and, especially, a need for relatively large amounts of freshfrozen tumor tissue. In addition,because they are based on whole-tissue homogenates, they are somewhat insensitive and nonspecific in accClunting for differences in the cellular composition ofsamples, such as rare tumor cells or contaminating benign cells that might be ER-positive. These problems motivated research into alternative methods of assessing ER status. including IHe. IHe has several potential advantages over LBA. including lower cost, easier technology, greater safety, the ability to evaluate a wide variety of samples (eg, fine-needle aspirates, frozen·' tissue, fixed archival tissue, etc). and higher~ensitivity and specificity in -theidentification ofrare tumorcells orcontaminating benign cells under direct microscopic visualization.
Since The few studies that specifically addressed subsets of patients not receiving any type of. systemic adjuvant therapy19.27,33.3S found, on average, only approximately a , 10% benefit in terms of DFS and/or OS associated with ER positivity. as assessed byIHC, which is similar to results from earlier LBA studies and emphasizes that ER status is a very weak prognostic factor, regardless of how it is measured. The results of this study confim1ed that ER status as determined by any method is a weak prognostic factor. Several smaH studies have evaluated the ability of ER status detem1ined by IHC to predict response to endocrine therapy in patients with advanced/metastatic breast cancer. 2 J.28.40-S7 In these studies, cumulatively involving over 1,000 patients treated with a variety of endocrine therapies, an average of approximately 70% with ER-positive tumors showeq. a significant .clinical response, whereas approximately 85% with ER-negative tumors did not, which was a iittle better than results with ER statuses measured by LBAs in some of the same studiesJ Much less is known about the ability of ER status determined by IRC to predict clinical outcome in the far larger number of patients with less advanced disease who receive adjuvant endocrine therapy, which was the primary focus of this study. In.our study, multivmiate analysis of the subset of patients receiving' adjuvant endocrine therapy alone (almost always tamoxifen; n = 517) revealed that ER positivity determined by IHC was superior to that' deter-. in-to our knowledge-the only other. similar study, also showed that· ER positivity detemiined by IHC in archival tissue predicted significantly improved DFS in 98 patients receivingadjuvanttamoxifentherapyalone;
In the sense that nearly all stu,dies to date have shown some clinical significance to assessing ER status by IHC, this methodology is approaching clinical validation, relative to published guidelines. 1-3 However, there are still persistent shortcomings in the. technical validation of this test. For, example, these studies used many different antibodies Ceg, H222, H226, D547, D75. 1D5) and a variety of usually 1479 arbitrary methods for scoring and interpreting results. In addition, the' majority utilized frozen-section IHC with antibody H222, which is very expensive and relatively insensitive in archival tissue (which has become the standard in most laboratories).
Our study developed and usedan IHC assay for measuring ER status, based on inexpensive, highly specific, commercially available reagents that are sensitive in archival tissue. We also developed a method of scoring results that was easy to leam and highly reproducible. Most importantly, the definition of ER positivity was calibrated to clinical outcome, in that it was based on the IHC score identifying the ,largest number of patients with significantly improved DFS in response to adjuvant endocrine therapy, .the primary reason in clinical practice for measuring ERstatus: With minimal training, pathologists' in our laboratory were in agreement on discriminating positive from negative tumors in 99% ofeases. ' The optimal cut point in our study was a total THe score of greater than 2, meaning that even patients whose tum9rs scored 3 (corresponding to as few asl % to 10% weakly positive cells) had a significantly improved response, compared with those who had lower scores, and tumors with scores of 3 comprised 6% of our total study population. Our low cut 'point by' IHC essentially agrees· with previous studies using LBA, in which ER levels as low as 4 to 10 fmol/mg protein were associated with significant rates of response to 'endocrine therapy. 1 0·12,. There .may .be several explanations as to why such low IHC scores predict favorable clinical outcome, including the possibility that the sensitivity of the test underestimates the proportion of ER-expressing cells or that low scores correspond to an ER-positive stem-celJ population. OurIHC cut point also provided clinically, significant results in various subsets of our study population (eg, as in untreated patients, DFS and OS in patients receiving endocrine therapy alone, and DFS and OS in patients receiving combined endocrine therapy and chemotherapy), which partially satisfies the recommendation that the utility of prognostic/predictive factor assays be demonstrated in Htest" and "validation" sets of patients. the laboratories that performed the origi-. naJ assays according. to the average . volume of assays they perform (we used a cut point of 100 cases per month).
There was less discrepancy with central HercepTest™ results in·the large-volume laboratories ( We tested the first.1 04 submitted cases for which eligibility was determined by using either HercepTest™ Table 1) . They were confirmed positive for gene amplification by ceritral FISH in 82 of 104 cases (79%; 95% a = 70% to 86%),Tn190fl04cases(18%;···95%····Cl = 11 % to 27%), they were neither strongly .positive by the HercepTest™ nor positiv·e for gene amplification by central review. Among these 19 cases, 10 were scored 0 or 1+ and nine were scored 2+ by cent,ral HercepTest™.
To explain the lack of reproducibility between the accredited laboratory and the central testing facility, we examined
BRIEF COlV1MUNICATIONS
Trastuzumab (Herceptin) is a humanized murine monoclonal antibody directed against the. HER2 growth factor receptor, which provides clinical benefits for patients with metastatic breast cancer that ·overexpresses HER2 (1, 2 Given the cost and potential cardiotoxicity of Herceptin, it is reasonable to recommend that· HERZ testing be done at large-volume reference laboratories. Since these data became ,available, we have implemented a laboratory approval process that considers both the laboratory volume and the quality of the assay. To date, 22 laboratories, 'all of which are experienced in both IHC and FISH, have been approved through this process. By performing· both assays,· quality can be cross-validated. We believe that such cross-validation may be the key to qUality assurance of HER~2· assays performed. . . . inthe. . . .community•. . . •lnaddition, all NSABP-approved laboratories use automated assay systems. probably reducing interassay variation. Accordingly, the NSABP has amended eligibility criteriaforB-31: only patients whose tumors score 3+. byIHC' performed by NSABP-approved reference laboratories or whose tumors demonstrate gene am- The reason for the trend favoring larger volume laboratories cannot be addressed directly because we have not performed a formal survey of laboratories. THe results can vary substantially because of multiple factors, including . time to fixation, duration. of fixation, processing, antigen retrieval, staining procedure, and staining interpretation (13) . Because strongly positive (3+) cases represent only 15%-20% of newly diagnosed breast cancer cases, pathologists in small-volume laboratories may over-anticipate positive cases, leading to an interpretation bias. Such bias would be less likely to occur in a large-volume ing results, the NSABP Pathology laboratory also perfonned FlSH on 81 of the cases (Table 2 , B). The concordance between the two FlSH assays was 77 of 81 (95%). This brief communication provides a snapshot of the quality of HER2 assays nationwide. We found. that an appreciable· percentage of community-based assay results, which were used to establish the eligibility of patients to participate inB"'3J., couldnot be.confirmed when tested in a central facility. These results may be surprising considering the studies (3-12) citing a high concordance between scores of 3+ in THC and FlSH. However, those studies were generallybased on data obtained from laboratories with, special expertise in HER2 research or from large-VOlume laborato- tHercepTest™ immunohistOChemistry is scored on a three-poinl scale. For eligibility in NSABP B-31. a positive score of 3+ was required. A negative score was 0-2+.
:j:PathVysion FlSH is scored as eilher positive or negative for HER2 gene amplification. §Small-volume laboratories were arbilrarily determined to perform no more than 99 lests per month.
IlLarge-volume laboratories were arbitrarily determined to perform at least 100 tests per month.
§Other lAC assays refers to any immunohistochemistry test that did nOt use the HercepTest™.
Test used for eligibility plification by FlSH from any laboratory would be allowed entry. It is our position that the question of whether FlSH or IHC is the better predictor of the response to Herceptin is . still unanswered. Although the analysis of Mass et al. (16) suggested the superiority of FlSH, the IHe used in that study was the Clinical Trials Assay. According· to the package insert for Herceptin1M (http://www.gene.com!gene/ productslinfonnationloncologylherceptinl insert.jsp), concordance between the two assays is relatively poor, especially when the immunostaining is scored as 2+. Furthennore, the response of micrometastatic tumor cells in the adjuvant setting may be different from that of cancer cells· in advanced disease, especially when given in combination with chemotherapy.
